This report was first published by Endpoints News. To see the original version, click here
Revolution Medicines reported Monday that its experimental RAS inhibitor called daraxonrasib succeeded in a registrational trial for pancreatic cancer.
And now, the company plans to ask the FDA to approve the therapy under the agency’s Commissioner’s National Priority Voucher program that’s meant to speed up review times for a small number of selected drugs.
您已阅读17%（449字），剩余83%（2227字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。